Adult ADHD treatment shows promise after phase 3 trials
New phase 3 clinical trial data suggests that the investigational drug centanafadine shows promise in treating adult ADHD. The drug, which acts as a norepinephrine, dopamine, and serotonin reuptake inhibitor, demonstrated improvements in executive function and emotional regulation alongside core ADHD symptoms.
Why it matters
If approved by the FDA, this first-in-class treatment could offer a new therapeutic option for adults struggling with ADHD symptoms that are not fully addressed by current medications.
The findings of two identical phase 3 clinical trials evaluating a first-in-class treatment for adults with ADHD showed promising results, said Otsuka Pharmaceutical recently at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (26-29 May) in Miami.
The report summarizes clinical trial findings and regulatory status without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in